• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/8/21 10:23:29 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care
    Get the next $GNMK alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 11 GENMARK DIAGNOSTICS INC COMMON STOCK Cusip #372309104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #372309104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,812,620 Item 6: 0 Item 7: 10,758,659 Item 8: 0 Item 9: 10,758,659 Item 11: 15.000% Item 12: HC Cusip #372309104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 10,758,659 Item 8: 0 Item 9: 10,758,659 Item 11: 15.000% Item 12: IN Item 1(a). Name of Issuer: GENMARK DIAGNOSTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 5964 LA PLACE COURT CARLSBAD, CA 92008 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 372309104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 10,758,659 (b) Percent of Class: 15.000% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 2,812,620 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 10,758,659 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of GENMARK DIAGNOSTICS INC. No one other person's interest in the COMMON STOCK of GENMARK DIAGNOSTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of GENMARK DIAGNOSTICS INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.
    Get the next $GNMK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNMK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNMK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®

    Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123 Browse in-de

    10/13/21 11:15:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash

    Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of March 12, 2021 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Geronimo Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and GenMark. The tender offer period will expire at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, April 21, 2021, unless the offer is extended. Roche

    3/25/21 12:40:00 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

    Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sampleGenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections              Basel, 15 March 2021 - Roc

    3/15/21 2:00:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    SEC Filings

    View All

    SEC Form 15-12B filed by GenMark Diagnostics, Inc.

    15-12B - GenMark Diagnostics, Inc. (0001487371) (Filer)

    5/3/21 4:02:03 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by GenMark Diagnostics, Inc.

    EFFECT - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/28/21 12:15:09 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by GenMark Diagnostics, Inc.

    S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/22/21 4:22:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GenMark Diagnostics downgraded by BTIG

    BTIG downgraded GenMark Diagnostics from Buy to Neutral

    3/17/21 7:31:42 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Cowen & Co. with a new price target

    Cowen & Co. downgraded GenMark Diagnostics from Outperform to Market Perform and set a new price target of $24.05 from $23.00 previously

    3/17/21 6:46:59 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Canaccord Genuity

    Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold

    3/16/21 10:34:41 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giles Lisa M. decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:57 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fox James decreased direct ownership by 100% to 0 units to cover taxes

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:12 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Kagnoff Michael decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:32 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    5/10/21 11:58:21 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    4/12/21 1:05:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by GenMark Diagnostics, Inc.

    SC 13D - GenMark Diagnostics, Inc. (0001487371) (Subject)

    3/26/21 9:07:58 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care